New drug quality attribute analysis is a systematic process of identifying, characterizing, and controlling the physical, chemical, and biological properties of drug substances and drug products that influence safety, efficacy, and quality. Built on the Quality by Design (QbD) framework described in ICH Q8, Q9, and Q11, critical quality attribute (CQA) analysis forms the scientific backbone of CMC development, regulatory submissions, and lifecycle management for both small molecules and biologics. This article provides a comprehensive technical overview of quality attribute testing samples, analytical items, methods, and applications in modern pharmaceutical development.
Technical Overview
New drug quality attribute analysis refers to the structured evaluation of all measurable properties of a pharmaceutical product that define its quality, with particular emphasis on critical quality attributes (CQAs)—those attributes whose variation must remain within appropriate limits to ensure the desired safety and efficacy profile. The concept is formally embedded in the Quality by Design (QbD) paradigm defined by ICH Q8(R2) (Pharmaceutical Development), ICH Q9(R1) (Quality Risk Management), and ICH Q11 (Development and Manufacture of Drug Substances), and is further supported by ICH Q14 (Analytical Procedure Development) for the associated analytical lifecycle.
Quality attribute analysis begins with the definition of the Quality Target Product Profile (QTPP), from which potential quality attributes are derived through risk assessment. Each attribute is then evaluated for criticality based on its potential impact on pharmacokinetics, pharmacodynamics, safety, and manufacturability. For small molecules, typical attributes include identity, assay, purity, degradation products, residual solvents, and polymorphic form. For biologics, the attribute space expands considerably to include primary and higher-order structure, post-translational modifications (PTMs) such as glycosylation, charge heterogeneity, aggregation, and biological potency.
Regulatory authorities in all major markets expect a science- and risk-based justification of criticality assignments, supported by robust analytical data generated under GLP/GMP-aligned conditions, often by accredited third-party laboratories. The analytical results feed directly into the establishment of a control strategy, design space definition, and specification setting in accordance with ICH Q6A (chemical substances) and ICH Q6B (biotechnological and biological products).
Testing Samples
Small Molecule Drug Substances (APIs)
Synthetic or semi-synthetic active pharmaceutical ingredients are analyzed for structural confirmation, chiral purity, crystal form, particle size distribution, and impurity profiles covering organic, inorganic, and residual solvent impurities per ICH Q3A, Q3B, Q3C, and Q3D guidelines.
Small Molecule Drug Products
Finished dosage forms—including tablets, capsules, injectables, suspensions, and topical formulations—are evaluated for content uniformity, dissolution performance, degradation products, and physicochemical stability across the proposed shelf life.
Biological Drug Substances
Monoclonal antibodies, recombinant proteins, fusion proteins, enzymes, and antibody-drug conjugates (ADCs) undergo comprehensive structural and functional characterization, including intact mass, peptide mapping, glycan profiling, charge variant analysis, and potency testing.
Advanced Therapy Medicinal Products
Cell therapy products, gene therapy vectors, mRNA therapeutics, vaccines, and plasmid DNA require attribute analysis covering vector identity, copy number, transduction efficiency, expression cassettes, residual host cell DNA/protein, and adventitious agent safety testing.
In-Process Materials and Excipients
Intermediates, key starting materials, excipients, and reference standards are characterized to support process understanding, supplier qualification, and analytical method traceability throughout development.
Testing Items
Quality attribute testing programs are typically organized around the following categories:
- Identity and structural confirmation: confirmation of molecular structure, sequence verification, isomeric and polymorphic form identification, and spectroscopic fingerprinting.
- Assay and content: quantitative determination of the active ingredient content, drug loading (for ADCs), and content uniformity in finished products.
- Purity and impurity profiling: related substances, degradation products, process-related impurities, residual solvents, elemental impurities, residual host cell proteins (HCP), residual host cell DNA, and residual reagents such as Protein A.
- Biological activity and potency: cell-based potency assays, binding affinity and kinetics, antiviral or cytotoxic activity, and mechanism-of-action functional assays.
- Physicochemical attributes: molecular weight distribution, charge heterogeneity, glycosylation profile, disulfide linkage mapping, aggregation and particulate levels, viscosity, osmolality, and pH.
- Safety attributes: endotoxin levels, bioburden, sterility, mycoplasma, and adventitious virus screening.
- Stability-indicating attributes: degradation kinetics under ICH Q1A stress and long-term conditions, including thermal, photolytic, oxidative, and hydrolytic challenge studies.
Testing Methods
Attribute analysis employs a battery of orthogonal analytical techniques, selected according to ICH Q2(R2) validation principles covering specificity, accuracy, precision, linearity, range, detection limit, and quantitation limit.
- Chromatographic techniques: reversed-phase HPLC/UPLC for purity and assay, size-exclusion chromatography (SEC) for aggregates and fragments, ion-exchange chromatography (IEX) for charge variants, HILIC for glycan separation, and GC for residual solvents.
- Mass spectrometry: high-resolution LC-MS for intact mass analysis, LC-MS/MS peptide mapping for sequence coverage and PTM localization, and MS-based characterization of drug-to-antibody ratio in ADCs.
- Electrophoretic and focusing methods: CE-SDS for purity, capillary isoelectric focusing (cIEF/icIEF) for charge heterogeneity, and SDS-PAGE for orthogonal purity confirmation.
- Spectroscopic and structural methods: NMR and FTIR for structural confirmation, UV-Vis for concentration, circular dichroism and intrinsic fluorescence for higher-order structure, and Raman spectroscopy for solid-state form analysis.
- Biological assays: ELISA and cell-based potency assays, surface plasmon resonance (SPR) and biolayer interferometry (BLI) for binding kinetics, and flow cytometry for cell-based mechanism-of-action assays.
- Molecular and compendial methods: qPCR and NGS for adventitious agent and residual DNA testing, ICP-MS for elemental impurities, Karl Fischer titration for water content, dissolution testing, and X-ray powder diffraction (XRPD) for polymorph identification.
- Bioinformatics-assisted characterization: multi-attribute method (MAM) workflows combining high-resolution MS with automated data processing for simultaneous monitoring of multiple quality attributes.
Methods are developed and validated in alignment with ICH Q2(R2) and Q14, with compendial procedures executed in accordance with the relevant pharmacopoeial standards (USP, Ph. Eur., JP, or Chinese Pharmacopoeia) as appropriate for the target markets.
Applications
New drug quality attribute analysis supports the entire product lifecycle, from discovery through commercial manufacturing:
- Preclinical and IND-enabling CMC packages: generating the structural, purity, and safety data required to support first-in-human clinical trial applications.
- NDA and BLA submissions: assembling comprehensive characterization data that justify specifications and control strategies for market authorization dossiers.
- Comparability studies: demonstrating analytical similarity following manufacturing scale-up, site transfer, or process changes, in line with ICH Q5E principles.
- Biosimilar development: conducting stepwise structural and functional similarity assessments against reference products to support extrapolation of clinical data.
- Control strategy and specification setting: converting attribute data into scientifically justified acceptance criteria, design spaces, and lifecycle control plans.
- Stability and shelf-life determination: attribute monitoring under ICH Q1 conditions to establish retest periods and expiry dating.
- Formulation and process development support: identifying which formulation and process parameters influence critical attributes, enabling QbD-based optimization.
- Reference standard qualification: characterizing in-house and compendial standards to anchor quantitative methods across the analytical lifecycle.
FAQ
What is the difference between a quality attribute and a critical quality attribute?
A quality attribute is any measurable physical, chemical, or biological property of a drug substance or product. A critical quality attribute is a subset whose variability has a direct, scientifically justified impact on safety or efficacy, and which must therefore be controlled within defined limits as part of the control strategy.
When should quality attribute analysis begin in drug development?
Attribute identification should begin as early as candidate selection, with criticality assessments refined progressively through preclinical and clinical development. Early analysis de-risks later-stage development by establishing baseline characterization before process and formulation changes occur.
Which regulatory guidelines govern quality attribute analysis?
The primary frameworks are ICH Q8(R2), Q9(R1), Q10, Q11, Q5E, and Q14, together with specification guidelines ICH Q6A and Q6B, impurity guidelines Q3 series and M7, and analytical validation guideline Q2(R2). Pharmacopoeial standards from USP, Ph. Eur., and JP supplement these frameworks.
How is attribute criticality assessed?
Criticality is typically evaluated using structured quality risk management tools such as failure mode and effects analysis (FMEA) or risk ranking and filtering, combining prior knowledge, mechanistic understanding, toxicological thresholds, and experimental data to rank each attribute's impact and uncertainty.
Do analytical methods for attribute testing require validation?
Yes. Methods intended to support regulatory submissions must be validated per ICH Q2(R2), while early-phase exploratory methods should be qualified to demonstrate scientific suitability. Lifecycle management of methods follows ICH Q14 principles.
Can quality attribute analysis be outsourced?
Yes. Many sponsors engage accredited third-party laboratories or GMP-compliant contract analytical facilities to perform attribute characterization, particularly for specialized techniques such as high-resolution mass spectrometry, glycan analysis, and cell-based potency assays, while retaining scientific oversight of data interpretation.